FDA proposes ban on bulk compounding of semaglutide and tirzepatide

On April 30, 2026, the U.S. Food and Drug Administration (FDA) announced it is considering removing glucagon-like peptide-1 (GLP-1) receptor agonists from the 503B bulks list , as there is no current clinical need for pharmacies to be able to compound these medications.

This could include drugs such as semaglutide (the active ingredient in Ozempic and Wegovy ), tirzepatide (the active ingredient in Zepbound and Mounjaro ), and liraglutide (the active ingredient in Victoza and Saxenda ). According to the FDA’s announcement, the organization is asking for submitted comments for or against this decision by the end of June 2026 before making their final determination.

Medical News Today spoke with 4 obesity experts to find out more about what the FDA’s 503B bulks list is, the potential future availability of compounded GLP-1 medications, and what alternatives may be available for users who may not be able to afford the brand name drugs.